2016
Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.
Barry DT, Cutter CJ, Beitel M, Kerns RD, Liong C, Schottenfeld RS. Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder. The Journal Of Clinical Psychiatry 2016, 77: 1413-1419. PMID: 27574837, PMCID: PMC6296217, DOI: 10.4088/jcp.15m09963.Peer-Reviewed Original ResearchConceptsOpioid use disorderCo-occurring chronic painChronic painAxis I DisordersUse disordersPsychiatric disordersI disordersMood disordersCo-occurring opioid use disorderBuprenorphine/naloxone treatmentNonopioid substance use disordersDSM-IV-TR Axis I DisordersCo-occurring psychiatric disordersAnxiety disordersMajority of patientsPersonality disorderMethadone maintenance treatmentTreatment of patientsComorbid psychiatric disordersLifetime mood disordersMajor depressive disorderStructured Clinical InterviewLifetime anxiety disorderSubstance use disordersTreatment Research Program
2013
Pain and Associated Substance Use among Opioid Dependent Individuals Seeking Office‐Based Treatment with Buprenorphine–Naloxone: A Needs Assessment Study
Barry DT, Savant JD, Beitel M, Cutter CJ, Moore BA, Schottenfeld RS, Fiellin DA. Pain and Associated Substance Use among Opioid Dependent Individuals Seeking Office‐Based Treatment with Buprenorphine–Naloxone: A Needs Assessment Study. American Journal On Addictions 2013, 22: 212-217. PMID: 23617861, PMCID: PMC3641684, DOI: 10.1111/j.1521-0391.2012.00327.x.Peer-Reviewed Original ResearchConceptsBuprenorphine-naloxone treatmentChronic painSubstance usePain intensityPast-week substance useCharacteristics of painCurrent pain intensityOpioid-dependent individualsTypical pain intensitySelf-reported substance useHigh rateBNT patientsBuprenorphine-naloxoneOpioid withdrawalPain frequencyPercent of respondentsPain durationPain locationPain subgroupsNerve damageOpioid dependencePain interferencePain typesConsecutive individualsPain
2012
Use of Conventional, Complementary, and Alternative Treatments for Pain Among Individuals Seeking Primary Care Treatment With Buprenorphine-Naloxone
Barry DT, Savant JD, Beitel M, Cutter CJ, Moore BA, Schottenfeld RS, Fiellin DA. Use of Conventional, Complementary, and Alternative Treatments for Pain Among Individuals Seeking Primary Care Treatment With Buprenorphine-Naloxone. Journal Of Addiction Medicine 2012, 6: 274-279. PMID: 23041680, PMCID: PMC3492534, DOI: 10.1097/adm.0b013e31826d1df3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesicsAnalgesics, OpioidBuprenorphineBuprenorphine, Naloxone Drug CombinationChronic PainCombined Modality TherapyComorbidityComplementary TherapiesFemaleHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPrimary Health CareTreatment OutcomeUtilization ReviewConceptsBuprenorphine-naloxone treatmentPain treatmentOpioid dependenceTreatment useCP groupSP groupPain treatment modalitiesPain-related treatmentsPain management servicesPrimary care treatmentLifetime useBuprenorphine-naloxoneOpioid medicationsPain groupPain statusCare treatmentTreatment modalitiesAlternative treatmentMeasures of demographicsPainMedical useMedicationsTreatmentUse of ConventionalEfficacyBrief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients
Tetrault JM, Moore BA, Barry DT, O'Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. Journal Of Substance Use And Addiction Treatment 2012, 43: 433-439. PMID: 22938914, DOI: 10.1016/j.jsat.2012.07.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineBuprenorphine, Naloxone Drug CombinationCounselingDelivery of Health Care, IntegratedFeasibility StudiesFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPsychotherapy, BriefSubstance Abuse DetectionTime FactorsTreatment OutcomeViral LoadConceptsEnhanced medical managementPhysician managementDetectable HIV viral loadHIV treatment settingsOpioid-negative urinesBuprenorphine/naloxoneHIV viral loadOpioid-dependent patientsPercentage of subjectsUntreated opioid dependenceExtended counselingHIV clinicHIV outcomesBuprenorphine/Medical managementOpioid dependenceViral loadDependent patientsExtensive counselingClinical trialsContinuous abstinenceNegative urineTreatment settingsGroup differencesCounselingPrevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment
Savant JD, Barry DT, Cutter CJ, Joy MT, Dinh A, Schottenfeld RS, Fiellin DA. Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment. Drug And Alcohol Dependence 2012, 127: 243-247. PMID: 22771144, PMCID: PMC3525769, DOI: 10.1016/j.drugalcdep.2012.06.020.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxone treatmentNon-opioid substancesNaloxone treatmentPrevalence of moodPsychiatric comorbidityDSM-IV Axis I DisordersMinority of patientsMethadone maintenance treatmentStructured Clinical InterviewAxis I DisordersPrevalent mood disorderCross-sectional surveyCurrent dysthymiaConsecutive patientsMaintenance treatmentMajor depressionTreatment outcomesI disordersMood disordersPast diagnosisPatientsClinical InterviewSectional surveyComorbiditiesPrevalence
2009
The Association between Cocaine Use and Treatment Outcomes in Patients Receiving Office‐Based Buprenorphine/Naloxone for the Treatment of Opioid Dependence
Sullivan LE, Moore BA, O'Connor PG, Barry DT, Chawarski MC, Schottenfeld RS, Fiellin DA. The Association between Cocaine Use and Treatment Outcomes in Patients Receiving Office‐Based Buprenorphine/Naloxone for the Treatment of Opioid Dependence. American Journal On Addictions 2009, 19: 53-58. PMID: 20132122, PMCID: PMC3107713, DOI: 10.1111/j.1521-0391.2009.00003.x.Peer-Reviewed Original ResearchConceptsOpioid-negative urinesBuprenorphine/naloxoneUrine toxicology testsWeeks of treatmentWorse treatment outcomesTreatment outcomesCocaine useTreatment retentionMean weekBuprenorphine/naloxone maintenanceGreater percentageToxicology testsUrine toxicology resultsOpioid dependenceToxicology resultsPatientsTargeted interventionsWeeksNaloxoneOutcomesTreatmentBaselineUrineAssociationPercentage
2008
Long‐Term Treatment with Buprenorphine/Naloxone in Primary Care: Results at 2–5 Years
Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, Barry DT, O'Connor PG, Schottenfeld RS. Long‐Term Treatment with Buprenorphine/Naloxone in Primary Care: Results at 2–5 Years. American Journal On Addictions 2008, 17: 116-120. PMID: 18393054, DOI: 10.1080/10550490701860971.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCombined Modality TherapyCounselingCross-Sectional StudiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHeroin DependenceHumansLong-Term CareMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPatient DropoutsPrimary Health CareSubstance Abuse DetectionTreatment OutcomeConceptsOpioid-dependent patientsAdverse eventsSerum transaminasesBuprenorphine/naloxone treatmentSerious adverse eventsBuprenorphine/naloxoneLong-term outcomesOffice-based treatmentIllicit drug useOpioid useClinical stabilityNaloxone treatmentPrimary outcomePatient satisfactionPrimary careTerm treatmentDrug useUrine samplesPatientsTreatmentTransaminaseOutcomesYearsModerate levelsPercent
2007
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors
Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O'Connor PG, Schottenfeld RS, Fiellin DA. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. Journal Of Substance Use And Addiction Treatment 2007, 35: 87-92. PMID: 17933486, PMCID: PMC2587397, DOI: 10.1016/j.jsat.2007.08.004.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxone treatmentNaloxone treatmentHIV risk behaviorsHIV riskRisk behaviorsHuman immunodeficiency virus (HIV) risk behaviorsDrug-related HIV riskHuman immunodeficiency virus (HIV) riskSex-related HIV risk behaviorsBuprenorphine/naloxoneIntravenous drug useOpioid-dependent personsPrimary care clinicsInconsistent condom useBuprenorphine/Care clinicsMethadone treatmentPrimary careDrug useSteady partnerCondom useBaselineWeeksTreatmentPatientsPatient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment
Barry DT, Moore BA, Pantalon MV, Chawarski MC, Sullivan LE, O’Connor P, Schottenfeld RS, Fiellin DA. Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment. Journal Of General Internal Medicine 2007, 22: 242-245. PMID: 17356993, PMCID: PMC1824745, DOI: 10.1007/s11606-006-0050-y.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxonePatient satisfactionBuprenorphine/naloxone treatmentDrug treatment historyOpioid-dependent patientsPrimary care officesOpioid-dependent subjectsSubstance use statusOverall satisfaction scoreOffice visit frequencyNaloxone treatmentParticipantsOne hundredPrimary outcomeCare officesFemale genderTreatment historyPatientsNaloxoneSatisfaction scoresEthnicity/raceTreatment locationUse statusVisit frequencyMedicationsTreatment
2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependence